Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.80 |
| ▸ | LMNA | P02545 | 2/20 | 0.80 |
| ▸ | HTT | P42858 | 1/20 | 0.80 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.69 |
| ▸ | PPARA | Q07869 | 1/20 | 0.65 |
| ▸ | PLAUR | Q03405 | 1/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | DHODH | Q02127 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | CCR6 | P51684 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | AURKA | O14965 | 1/20 | 0.55 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.55 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.55 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.55 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzaldehyde SCHEMBL22471883 | 0.91 | KDM4E (0.68) | KDM4ELMNAHTTPDE10APPARA | |
| SCHEMBL31620698 | 0.89 | KDM4E (1.00) | KDM4ELMNAHTTPDE10APPARA | |
| SCHEMBL11810641 | 0.86 | PDE10A (0.70) | KDM4ELMNAHTTPDE10APPARA | |
| SCHEMBL8324266 | 0.86 | KDM4E (0.64) | KDM4ELMNAHTTPDE10APPARA | |
| SCHEMBL13958056 | 0.84 | CCR6 (0.68) | KDM4ELMNAHTTPDE10APPARA | |
| SCHEMBL8619739 | 0.82 | PPARA (0.69) | KDM4ELMNAHTTPDE10APPARA | |
| SCHEMBL28019600 | 0.82 | CCR6 (0.67) | KDM4ELMNAHTTPDE10APPARA | |
| SCHEMBL22471898 | 0.82 | AURKA (0.78) | KDM4ELMNAHTTPDE10APPARA | |
| SCHEMBL8619775 | 0.82 | PPARA (0.64) | KDM4ELMNAHTTPDE10APPARA | |
| SCHEMBL10758255 | 0.82 | PDE10A (0.64) | KDM4ELMNAHTTPDE10APPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4617270-A1 | ISOINDOLINONE DERIVATIVE HAVING QUINOLINE AMIDE STRUCTURE, AND USE THEREOF | Oncord Bio Inc (KR) | 2025-09-17 | — | — | EP | disclosed |
| CN-120152966-A | Isoindolinone derivative with quinolinamide structure and application thereof | 昂科德生物株式会社 | 2025-06-13 | — | — | CN | disclosed |
| WO-2024101764-A1 | ISOINDOLINONE DERIVATIVE HAVING QUINOLINE AMIDE STRUCTURE, AND USE THEREOF | 주식회사 온코드바이오 | 2024-05-16 | — | — | WO | disclosed |
| US-20220169640-A1 | PRODUCTION METHOD OF QUINOLINECARBOXAMIDE DERIVATIVE OR PRODUCTION INTERMEDIATE THEREOF | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 2022-06-02 | — | — | US | disclosed |
| EP-3943159-A1 | PRODUCTION METHOD OF QUINOLINECARBOXAMIDE DERIVATIVE OR PRODUCTION INTERMEDIATE THEREOF | Kabushiki Kaisha Yakult Honsha (JP) | 2022-01-26 | — | — | EP | disclosed |
| WO-2005118580-A2 | TRICYCLIC COMPOUNDS AS INHIBITORS OF THE HYPOXIC SIGNALING PATHWAY | THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH (US) | 2005-12-15 | — | — | WO | disclosed |
| US-6906193-B2 | N-type calcium channel antagonists for the treatment of pain | ASTRAZENECA AB (SE) | 2005-06-14 | — | — | US | disclosed |
| US-20040053964-A1 | N-type calcium channel antagonists for the treatment of pain | ASTRAZENECA AB (SE) | 2004-03-18 | — | — | US | disclosed |
| EP-1339689-A1 | N-TYPE CALCIUM CHANNEL ANTAGONISTS FOR THE TREATMENT OF PAIN | AstraZeneca AB (SE) | 2003-09-03 | — | — | EP | disclosed |
| WO-2002036568-A1 | N-TYPE CALCIUM CHANNEL ANTAGONISTS FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2002-05-10 | — | — | WO | disclosed |
| EP-0726254-B1 | Quinoline-4-carbonylguanidine derivates, process for producing the same and pharmaceutical preparations containing the compounds | MITSUI TOATSU CHEMICALS (JP) | 1998-05-06 | — | — | EP | disclosed |
| US-5627193-A | MEDICAL DIAGNOSIS, CARDIOVASCULAR DIAORDERS AND PROTECTION OF ORGANS FOR TRANSPLANTATION | MITSUI TOATSU CHEMICALS, INC. (JP) | 1997-05-06 | — | — | US | disclosed |
| EP-0726254-A1 | Quinoline-4-carbonylguanidine derivates, process for producing the same and pharmaceutical preparations containing the compounds | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1996-08-14 | — | — | EP | disclosed |
| EP-0206802-B1 | SUBSTITUTED QUINOLINE DERIVATIVES | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1993-09-01 | — | — | EP | disclosed |
| US-4904659-A | Substituted quinoline derivatives and pharmaceutical compositions thereof | DEVELOPMENT FINANCE CORPORATION OF NEW ZELAND (NZ) | 1990-02-27 | — | — | US | disclosed |
| EP-0206802-A2 | Substituted quinoline derivatives | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1986-12-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220169640-A1 | PRODUCTION METHOD OF QUINOLINECARBOXAMIDE DERIVATIVE OR PRODUCTION INTERMEDIATE THEREOF | BCKDK, CBR3, NQO2 | KDM4E 363/4885LMNA 1893/4885HTT 2685/4885 |
| US-20040053964-A1 | N-type calcium channel antagonists for the treatment of pain | CACNA1E, CACNA1B, CACNA1A | KDM4E 4425/4885LMNA 3096/4885HTT 2827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.